Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) have been given a consensus rating of "Buy" by the nine analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $53.78.
A number of equities analysts have commented on PTGX shares. StockNews.com lowered Protagonist Therapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Protagonist Therapeutics in a research report on Tuesday, December 10th. Wedbush reaffirmed an "outperform" rating and issued a $58.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Truist Financial assumed coverage on shares of Protagonist Therapeutics in a research note on Monday, September 9th. They set a "buy" rating and a $60.00 price objective on the stock. Finally, The Goldman Sachs Group initiated coverage on shares of Protagonist Therapeutics in a research report on Friday, December 6th. They issued a "neutral" rating and a $47.00 target price for the company.
View Our Latest Stock Analysis on PTGX
Shares of PTGX opened at $41.49 on Friday. Protagonist Therapeutics has a 12 month low of $20.88 and a 12 month high of $48.89. The firm's 50 day moving average is $44.02 and its 200-day moving average is $40.88. The stock has a market capitalization of $2.47 billion, a PE ratio of 15.60 and a beta of 2.18.
In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the sale, the chief executive officer now directly owns 435,208 shares of the company's stock, valued at $20,437,367.68. The trade was a 15.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Arturo Md Molina sold 1,906 shares of the firm's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $40.98, for a total transaction of $78,107.88. Following the transaction, the insider now directly owns 46,444 shares of the company's stock, valued at $1,903,275.12. The trade was a 3.94 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 209,863 shares of company stock worth $9,689,847. Corporate insiders own 5.40% of the company's stock.
Several institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. raised its position in Protagonist Therapeutics by 3,099.4% during the 3rd quarter. Principal Financial Group Inc. now owns 320,832 shares of the company's stock worth $14,437,000 after purchasing an additional 310,804 shares during the last quarter. Franklin Resources Inc. raised its position in shares of Protagonist Therapeutics by 127.2% during the third quarter. Franklin Resources Inc. now owns 81,591 shares of the company's stock worth $3,782,000 after acquiring an additional 45,674 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in shares of Protagonist Therapeutics during the third quarter worth about $909,000. Geode Capital Management LLC lifted its stake in shares of Protagonist Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,374,697 shares of the company's stock worth $61,873,000 after acquiring an additional 3,528 shares during the period. Finally, Barclays PLC boosted its holdings in Protagonist Therapeutics by 223.6% in the third quarter. Barclays PLC now owns 126,995 shares of the company's stock valued at $5,714,000 after acquiring an additional 87,755 shares during the last quarter. Institutional investors own 98.63% of the company's stock.
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Protagonist Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protagonist Therapeutics wasn't on the list.
While Protagonist Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.